Results 221 to 230 of about 102,686 (380)

Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background and aim Stridor and sleep apnea syndrome (SAS) are common in multiple system atrophy (MSA). Retrospective cohort studies have yielded conflicting results regarding the consequences of stridor and SAS on the disease course. This study aimed to assess the prognostic significance of stridor and SAS, as well as the potential survival ...
Pauline Dodet, Cecile Proust‐Lima, Federico Sirna, David Bendetowicz, Giulia Lazzeri, Rachel Debs, Anna Delamarre, Margaux Dunoyer, Margherita Fabbri, Claire Georges, Imad Ghorayeb, David Grabli, Cécile Londner, Anne Pavy‐Le Traon, Maxime Patout, Olivier Rascol, Isabelle Arnulf, Alexandra Foubert‐Samier, Wassilios G. Meissner   +18 more
wiley   +1 more source

Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder

, 2023
Xuan Zhang, Li Ma, Danqi Liang, Bingxin Song, Jingshan Chen, Yaqin Huang, Lin Xu, Peng Zhao, Wei Wu, Nan Zhang, Rong Xue   +10 more
openalex   +2 more sources

Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD  [PDF]

, 2020
Sunny Kumar, Daniel J. Phaneuf, Pierre Cordeau, Hejer Boutej, Jasna Križ, Jean‐Pierre Julien   +5 more
openalex   +1 more source

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta‐Analysis

Movement Disorders, EarlyView.
Abstract Background The activation of the NOD‐, LRR‐ and pyrin domain‐containing protein 3 (NLRP3) inflammasome and associated immune dysregulation is one of the key pathological processes preceding and accompanying α‐synuclein pathology, neuronal damage, and cell death in Parkinson's disease (PD).
Alina‐Măriuca Marinescu, Venissa Machado, Gennaro Pagano, Nicoletta Milani Muelhardt, Thomas Kustermann, Eva Zsuzsanna Mracsko, Kathrin Brockmann, Nima Shariati, Judith Anzures‐Cabrera, Bastian Zinnhardt   +9 more
wiley   +1 more source

Editorial: Blood Biomarkers of Neurodegenerative Diseases

Frontiers in Molecular Neuroscience, 2022
Thomas K. Karikari, Thomas K. Karikari, Nicholas J. Ashton, Nicholas J. Ashton, Nicholas J. Ashton, Nicholas J. Ashton, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Kaj Blennow, Kaj Blennow   +12 more
doaj   +1 more source

Clinical and neuropathological associations of plasma Aβ₄₂/Aβ₄₀, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders [PDF]

Binita Rajbanshi, Igor Araújo, Lawren VandeVrede, Peter A. Ljubenkov, Adam M. Staffaroni, Hilary W. Heuer, Argentina Lario Lago, Eliana Marisa Ramos, Leonard Petrucelli, Tania Gendron, Jeffrey L. Dage, William W. Seeley, Lea T. Grinberg, Salvatore Spina, Randall J. Bateman, Howard J. Rosen, Bradley F. Boeve, Adam L. Boxer, Julio C. Rojas   +18 more
openalex   +1 more source

Perampanel Blocks Transsynaptic α‐Synuclein Propagation and Neurodegeneration in a Mouse Model of Lewy Body Disease

Movement Disorders, EarlyView.
Abstract Background Transsynaptic α‐synuclein propagation plays a crucial role in the progression of Lewy body disease. We previously demonstrated that an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, perampanel, blocks neuronal uptake of α‐synuclein preformed fibrils (PFFs) in an activity‐dependent manner.
Jun Ueda, Norihito Uemura, Jiarui Chang, Tetsuya Hirato, Tomoyuki Ishimoto, Miki Oono, Shuichi Matsuzawa, Riki Matsumoto, Hodaka Yamakado, Ryosuke Takahashi   +9 more
wiley   +1 more source

Correlation analysis of serum neurofilament light chain and glial fibrillary acidic protein levels with amyotrophic lateral sclerosis. [PDF]

Sci Rep
Ji C, Li P, Ma S, Li J, Zhou J, Zhu J, Dong D, Yang T, Yang P.   +8 more
europepmc   +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M. Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N.H. Nudelman, Andrew Siderowf, Caroline M. Tanner, Thomas F. Tropea, Tatiana Foroud, Lana M. Chahine, Brit Mollenhauer, Kalpana M. Merchant, Douglas Galasko, Christopher S. Coffey, Roseanne D. Dobkin, Ethan G. Brown, Roy N. Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez‐Latapi, Nicola Pavese, Kathleen L. Poston, the Parkinson's Progression Markers Initiative   +30 more
wiley   +1 more source

Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey. [PDF]

BMC Neurol
Gnanapavan S, Arun T, Gallagher P, Rushworth M, Marsh J, Kondori NR.   +5 more
europepmc   +1 more source